Shulamith Rizel

1.8k total citations
46 papers, 1.2k citations indexed

About

Shulamith Rizel is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Shulamith Rizel has authored 46 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 20 papers in Cancer Research and 11 papers in Genetics. Recurrent topics in Shulamith Rizel's work include Breast Cancer Treatment Studies (18 papers), Cancer Treatment and Pharmacology (8 papers) and BRCA gene mutations in cancer (6 papers). Shulamith Rizel is often cited by papers focused on Breast Cancer Treatment Studies (18 papers), Cancer Treatment and Pharmacology (8 papers) and BRCA gene mutations in cancer (6 papers). Shulamith Rizel collaborates with scholars based in Israel, United States and Cyprus. Shulamith Rizel's co-authors include Salomon M. Stemmer, Irit Ben‐Aharon, Ruth Shalgi, Noa Ben-Baruch, Lior Soussan‐Gutman, Hadas Bar‐Joseph, Rinat Yerushalmi, Aarón Sulkes, Adva Yeheskel and Vincent A. Miller and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Shulamith Rizel

44 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shulamith Rizel Israel 18 526 418 329 273 269 46 1.2k
L. Phuong United States 19 502 1.0× 331 0.8× 572 1.7× 360 1.3× 135 0.5× 42 1.3k
Shelly Cummings United States 20 431 0.8× 374 0.9× 1.1k 3.3× 370 1.4× 197 0.7× 42 1.6k
Uwe Güth Switzerland 22 694 1.3× 457 1.1× 165 0.5× 205 0.8× 139 0.5× 102 1.4k
Matthias W. Beckmann Germany 17 394 0.7× 224 0.5× 539 1.6× 415 1.5× 121 0.4× 51 1.2k
Kerry J. Rodabaugh United States 20 497 0.9× 292 0.7× 175 0.5× 477 1.7× 84 0.3× 50 1.5k
Alicia Beeghly‐Fadiel United States 24 529 1.0× 430 1.0× 295 0.9× 433 1.6× 60 0.2× 74 1.3k
Jurandyr Moreira de Andrade Brazil 21 690 1.3× 290 0.7× 89 0.3× 317 1.2× 171 0.6× 114 1.5k
Pascaline Berthet France 15 425 0.8× 196 0.5× 513 1.6× 403 1.5× 79 0.3× 34 1.2k
Alessia Levaggi Italy 16 494 0.9× 223 0.5× 167 0.5× 180 0.7× 622 2.3× 43 1.1k
Javaid Iqbal Canada 15 1.1k 2.0× 782 1.9× 430 1.3× 286 1.0× 92 0.3× 23 1.8k

Countries citing papers authored by Shulamith Rizel

Since Specialization
Citations

This map shows the geographic impact of Shulamith Rizel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shulamith Rizel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shulamith Rizel more than expected).

Fields of papers citing papers by Shulamith Rizel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shulamith Rizel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shulamith Rizel. The network helps show where Shulamith Rizel may publish in the future.

Co-authorship network of co-authors of Shulamith Rizel

This figure shows the co-authorship network connecting the top 25 collaborators of Shulamith Rizel. A scholar is included among the top collaborators of Shulamith Rizel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shulamith Rizel. Shulamith Rizel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stemmer, Salomon M., Mariana Steiner, Shulamith Rizel, et al.. (2019). Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy. npj Breast Cancer. 5(1). 41–41. 23 indexed citations
2.
Goldvaser, Hadar, Shulamith Rizel, Daniel Hendler, et al.. (2017). The association between smoking and breast cancer characteristics and outcome. BMC Cancer. 17(1). 624–624. 24 indexed citations
3.
Stemmer, Salomon M., Shulamith Rizel, David Geffen, et al.. (2017). Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry. npj Breast Cancer. 3(1). 32–32. 68 indexed citations
4.
Sulkes, Aarón, Tzippy Shochat, Daliah Tsoref, et al.. (2016). Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations. Breast Cancer Research and Treatment. 157(3). 511–516. 29 indexed citations
5.
Yerushalmi, Rinat, Hadar Goldvaser, Aarón Sulkes, et al.. (2014). Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 &12 in Breast Cancer Patients: A Retrospective Analysis. PLoS ONE. 9(10). e107273–e107273. 7 indexed citations
6.
Kundel, Yulia, Nicola J. Nasser, Ofer Purim, et al.. (2013). Phase II Study of Concurrent Capecitabine and External Beam Radiotherapy for Pain Control of Bone Metastases of Breast Cancer Origin. PLoS ONE. 8(7). e68327–e68327. 6 indexed citations
7.
Ben‐Aharon, Irit, Liat Vidal, Shulamith Rizel, et al.. (2013). Bisphosphonates in the Adjuvant Setting of Breast Cancer Therapy—Effect on Survival: A Systematic Review and Meta-Analysis. PLoS ONE. 8(8). e70044–e70044. 34 indexed citations
8.
Stemmer, Salomon M., Shmuel Klang, Noa Ben-Baruch, et al.. (2013). The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients. Breast Cancer Research and Treatment. 140(1). 83–92. 34 indexed citations
9.
Bar‐Joseph, Hadas, et al.. (2010). Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reproductive Toxicology. 30(4). 566–572. 76 indexed citations
10.
Ben‐Aharon, Irit, et al.. (2010). Doxorubicin-induced ovarian toxicity. Reproductive Biology and Endocrinology. 8(1). 20–20. 127 indexed citations
11.
Yerushalmi, Rinat, Mordechai R. Kramer, Shulamith Rizel, et al.. (2009). Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study. Annals of Oncology. 20(3). 437–440. 14 indexed citations
12.
Korach, Jacob, et al.. (2006). Vulvar cancer metastatic to the breast. Gynecologic Oncology. 103(3). 1144–1146. 10 indexed citations
13.
Evron, Ella, Hadassah Goldberg, Alexander Kuzmin, et al.. (2006). Breast cancer in octogenarians. Cancer. 106(8). 1664–1668. 33 indexed citations
14.
Stemmer, Salomon M., et al.. (2004). High-Dose Chemotherapy and Autologous Stem Cell Transplant in Women With De Novo Chemosensitive Metastatic Breast Cancer. American Journal of Clinical Oncology. 27(3). 250–255. 2 indexed citations
15.
16.
Ron, Ilan G., Nely Wigler, Riva Borovik, et al.. (2002). CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) Versus CNF (Cyclophosphamide, Mitoxantrone, 5-Fluorouracil) as Adjuvant Chemotherapy for Stage II Lymph-Node Positive Breast Cancer. American Journal of Clinical Oncology. 25(5). 520–522. 1 indexed citations
17.
Ron, Ilan G., Nely Wigler, Riva Borovik, et al.. (2001). CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) Versus CNF (Cyclophosphamide, Mitoxantrone, 5-Fluorouracil) as Adjuvant Chemotherapy for Stage II Lymph-Node Positive Breast Cancer. American Journal of Clinical Oncology. 24(4). 323–327. 7 indexed citations
18.
Miles, David, J. O’Shaughnessy, Guadalupe Cervantes, et al.. (2001). Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: analysis of post-study therapy.. Breast Cancer Research and Treatment. 69(3). 287–287. 12 indexed citations
19.
Shiri‐Sverdlov, Ronit, Ruth Gershoni‐Baruch, Walter H. Gotlieb, et al.. (2001). The Tyr978X <i>BRCA1</i> Mutation in Non-Ashkenazi Jews: Occurrence in High-Risk Families, General Population and Unselected Ovarian Cancer Patients. Public Health Genomics. 4(1). 50–55. 30 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Phuong Breakdown of academic impact, for papers by Shelly Cummings Breakdown of academic impact, for papers by Uwe Güth Breakdown of academic impact, for papers by Matthias W. Beckmann Breakdown of academic impact, for papers by Kerry J. Rodabaugh Breakdown of academic impact, for papers by Alicia Beeghly‐Fadiel Breakdown of academic impact, for papers by Jurandyr Moreira de Andrade Breakdown of academic impact, for papers by Pascaline Berthet Breakdown of academic impact, for papers by Alessia Levaggi Breakdown of academic impact, for papers by Javaid Iqbal
Rankless by CCL
2026